ABSTRACT
Purpose:
To determine the intraocular pressure–lowering efficacy and adverse effects of travoprost and bimatoprost.
Methods:
Patients who were newly diagnosed as POAG at the outpatient department of our clinic between April 2002 and March 2005 and received topical anti-glaucoma medical therapy, were enrolled in this retrospective study. The cases were divided into two treatment groups for administration of travoprost(Group 1) and bimatoprost(Group 2). Eightythree eyes of 45 patients were followed up for 8.92(SD: 4.347) months in group 1 and 9.72(SD: 4.91) months in ngroup 2. Intraocular pressure changes, cup-to-disc ratios, visual field findings, central corneal pachymetry, ocular and systemic adverse effects, need for combination therapy and need for surgical therapy were followed and all of the findings were compared.
Results:
The mean pre-treatment IOP of group 1 was 25.29 mmHg while the mean post-treatment IOP was 17.80 mmHg and the mean decrease in IOP of 7.49 mmHg(29.61% ). In group 1, the most common ocular side effects were foreign body sensation in 4 patients(19.51%), ocular hyperemia in 2 patients (%9.75) and eyelash lengthening in 2 patients (%9.75). We switched the medical therapy in 2 patients (%9.75), started combined medical therapy in 6 patients(%24.39) and performed trabeculectomy in 3 patients(%12.19). In bimatoprost group(group 2) the mean pre-treatment IOP was 23.64 mmHg while the mean post-treatment IOP was 17.64 mmHg and the mean decrease in IOP was 6.00 mmHg (%25.38). In group 2 the most common ocular side effects were foreign body sensation in 6 patients (%28.57), ocular hyperemia in 5 patients (%23.80) and eyelash lengthening in 1 patient (%4.76). We switched the medical therapy in 2 patients (%9.52) and started combined medical therapy in 3 patients (%14.28). There was no statistical difference between two groups in IOP lowering effect (p=0.556).
Conclusion:
Both travoprost and bimatoprost are effective choice choices in reducing IOP in patients with POAG.
Keywords:
Primary open angle glaucoma, ocular hypertension, travoprost, bimatoprost
References
1The AGIS Investigators , 7. The relationship between control of intraocular pressure and visual field deterioration. The advanced glaucoma intervention study (AGIS):Am J Ophthalmol 2000,130-429
2Goldberg I, Relationship between intraocular pressure and preservation of visual fields in glaucoma. Surv Ophthalmol 2003,48-3
3Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL, Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002,47-53
4Eisenberg DL, Toris CB, Camras CB, Bimatoprost and Travoprost : a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002,47-105
5Toris BC, Gabelt TB, Kauffman LP, Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008,53-107
6Liang Y, Woodward DF, Guzman VM, LI C, Scott DF et all, Identification and pharmacological characterization of the prostaglandin FP and FP receptor variant complexes. Br J Ophthalmol 2008,154-1079
7Soltau BJ, Zimmerman TJ, Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol 2002,47-2
8Netland PA, Landry T, Sullivan EK, Andrew R, Silver L,Weiner A,Mallick S, Dickerson J, Bergamini MVW, Robertson SM, Davis AA: The Travoprost Study Group: Travoprost compared with latanoprost and timolol, in patients with open-angle glaucoma or ocular hypertension, Am J Ophthalmol 2001,132-472
9Sherwood M, Brandt J :Bimatoprost Study Groups 1 and 2, Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice daily in patients with elevated intraocular pressure. Surv. Ophthalmol 2001,45
10Cohen JS, Gross RL, Cheetmam JK, VanDenburgh AM, Bernstein P, Whitcup SM, Two &ndashyear double &ndashmasked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.Surv Ophthalmol 2004,49-45
11Parrish RK, Palmerg P, Sheu WP, A Comparison of Latanoprost, Bimatoprost, and Travoprost in Patients with Elevated Intraocular Pressure. A 12-week, Randomized, Masked-evaluator Multicenter study. Am J Ophthalmol 2003,135-688
12Cantor L, Hoop JS, Morgan L, WuDunn D, Catoria Y, The Bimatoprost- Travoprost Study Group, Intraocular pressure&ndashlowering efficacy of bimatoprost 0,003% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006,90-1370
13Alagöz G, Gürel K, Bayer A, Serin D, Çelebi S, Kukner S, A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 2008,222-88
14zdemir N, zcan AA, Bilgiç E, Bimatoprost, Latanoprost, Travoprost&rsquoun Primer Açik Açili Glokom Olgularin da Erken Dönem Yan Etkileri ve Göz Içi Basinci Üzerine Etkinligi. T. Oft. Gaz. 2004,33-376
15Noecker R, Earl ML, Mundorf T, Silverstein SM, Phillips MP, Comparing bimatoprost and travoprost in black Americans . Curr Med Res Opin. 2006,22-2175
16Akyol S, Köz G, Yarangümeli A, Elhan AI, Kural G, Travaprost, Latanoprost ve bimatoprostun göz içi basinci ve görme alani üzerindeki etkilerinin karsilastirilmasi:Ön çalisma. Türkiye Klinikleri Oftalmoloji Dergisi 2006,15-18
17Stewart WC, Kolkler AE, Stewart JA, Leech J, Jackson AL, Conjonctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003,135-314
18Tosti A, Pazzaglia M, Voudouris S, Tosti G, Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004,51-149
19Wand M, Gaudio AR, Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. Mar 133(3) 2002
20Stjernschantz JW, Albert DM, Hu DN, Drago F, Wistrand PJ, Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002,47-162
21Wolf R, Matz H, Zalish M, Pollack A, Orion E, Prostaglandin analogs for hair growth: great expectations. Dermatol Online 2003,9
22Johnstone MA, Albert DM, Prostaglandin-induced hair growth. Surv Ophthalmol 2002,47-185
